Skip to main content

20% Price Hike Among Pfizer Drugs

The increasing cost of drug has been the subject of concern and review - by legislators, reporters and patients.

The Financial Times has reviewed the annual price increases for the 91 drugs in Pfizers portfolio, showing an average price increase by 20 percent in the past year.

This includes Viagra and Lyrica.

Drug pricing has become a highly publicized and contentious issue. Many manufacturers are pledging to be more transparent to address the concerns of payers, patients and politicians.

Price hikes are common.  The cost of three top-selling TNF inhibitors has risen from $18,000 per year in 2000 to nearly $48,000 per year in 2017.

Companies like Sanofi, AbbVie, Allergan and Novo Nordisk have announced their price increases would be in the single-digit percentage range this year.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject